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Abstract
Background: Peripheral artery disease (PAD) is a narrowing or blocking of the arteries due to
plaque buildup, which prevents oxygen, blood, and other nutrients from getting to the legs. When
this buildup reaches a certain point, it becomes atherosclerosis, which is more prevalent in a
smoker. Smoking intensifies the problem of plaque buildup if an individual already suffers from
PAD. When an individual smokes, the nicotine causes the arteries to constrict and narrow,
reducing blood flow further. The ankle-brachial index (ABI) is a simple, cost-effective
diagnostic test to identify the presence of PAD which will improve patient outcomes.
Purpose: This DNP project aimed to increase routine screening for PAD in high-risk patients by
utilizing an evidence-based screening protocol.
Methods: This process change project consisted of modifying the current process used in a
cardiology clinic to increase screening of PAD in adult smokers. Data collected from a
retrospective chart review before implementation of the protocol was compared to amount of
screening that occurred following implementation of the protocol.
Results: There was a statistically significant increase (p=.0007) in rate of screenings from preintervention (3.4%) to post-intervention (47.6%). There was no statistically significant difference
(p=.018) between the pre-intervention group (3.4%) and the post-intervention group (19.0%) on
the detection of PAD.
Conclusion: This project showed the importance of identifying peripheral artery disease in highrisk patients and increased screening for peripheral artery disease in smokers aged 50 and older.
Keywords: peripheral artery disease, ankle-brachial index, smoking
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Project Ankle-Brachial Index: Implementation of an Evidence-based Peripheral Artery
Disease Protocol
Gerhard and Gornik (2017) recognized that lower extremity peripheral artery disease
(PAD) is a common cardiovascular disease that affects approximately 8.5 million Americans
above 40 years of age and 202 million people worldwide. It is associated with significant
morbidity, mortality, and quality of life (QoL) impairment. Caused by atherosclerosis or plaque
buildup, PAD reduces blood flow in peripheral arteries that carry blood away from the heart to
other body parts (Gerhard & Gornik, 2017). In 2016, the American Heart Association (AHA)
updated its guidelines for managing patients with lower extremity PAD (Appendix A).
This project aimed to address the lack of consistency in screening for PAD in high-risk
patients. The American Heart Association (2021) defines high-risk patients as one of the
following: (a) age≥65 years; (b) age 50-64 years, with risk factors for atherosclerosis (e.g.,
diabetes mellitus, history of smoking, hyperlipidemia, hypertension) or family history of PAD;
(c) age <50 years, with diabetic mellitus and one additional risk factor for atherosclerosis, and
(d) individuals with known PAD. In patients with a history or physical examination findings
suggestive of PAD, the resting ankle-brachial index (ABI), with or without segmental pressures
and waveforms, is recommended to establish the diagnosis (American Heart Association, 2021).
Background
Bevan and White Solaru (2020) identified PAD as a chronic, atherosclerotic disease that
results in limb-associated complications such as intermittent claudication, gangrene, and
functional impairment. Sequelae requiring amputation carry a mortality rate of ≤50% at one year
(Bevan & White Solaru 2020). Gerhard and Gornik (2017) recognized that PAD presents in

9
many clinical forms, many asymptomatic. Knowing the risk factors for lower extremity PAD
will assist with diagnosing and treating this disorder.
Tobacco use is one of the most substantial risk factors for lower extremity PAD. There is
a robust correlation between smoking and PAD; approximately 90% of patients with PAD have a
history of smoking. Smoking even half a pack of cigarettes a day may increase the risk of
having PAD by up to 50% (Gerhard & Gornik, 2017). Bevan and White Solaru (2020) observed
only about 10% to 25% of adults with PAD have symptoms of intermittent claudication. Another
20% to 50% are asymptomatic and do not have leg symptoms. In 1% to 2% of adult patients, a
severe form of lower extremity critical limb ischemia has been observed. The medical
community has widely disregarded asymptomatic PAD due to the erroneous belief that it is
benign (Bevan & White Solaru 2020).
Contrary to this belief, Criqui and Matsushita (2021) found asymptomatic and
symptomatic PAD patients similarly increased cardiovascular mortality risk. Early recognition of
the clinical manifestations of PAD and the use of guideline-directed medical treatment will help
improve the quality of care for these patients. The ABI can screen for and diagnose PAD in the
primary care setting. An ABI of less than 0.9 is associated with a two- to four-fold increase in
relative risk for cardiovascular events and all-cause mortality. The AHA recommends ABI
screening for patients 50 years and older with a smoking history (Criqui & Matsushita, 2021).
Health Risks
American Heart Association (2021) identified smoking as the leading risk factor for
clinical cardiovascular disease directly affecting atherosclerosis. Studies have shown smoking
affects the composition and distribution of blood lipids, accelerates the formation of aortic
plaques, and increases the total cholesterol content, thereby inducing atherosclerosis. Smoking
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contributes to endothelial dysfunction and monocytes' activation in PAD formation. Cigarettes
also cause the production of various chemokines and proinflammatory cytokines. PAD is more
prevalent in smokers because of the lack of relaxation and contraction of smooth muscle in the
arterial wall. PAD can lead to complications, including trouble managing daily activities without
help due to reduced mobility, chronic, long-term, or poor blood flow in the leg, called critical
limb ischemia, serious infections, or a sudden drop in blood flow to the leg, called acute limb
ischemia. Acute limb ischemia (ALI) is a medical emergency. Over half of all amputations are
due to vascular conditions, including PAD. These conditions could result in the need for
amputation (American Heart Association, 2021).
Health Benefits from Screening
Haigh (2016) found two potential reasons to consider PAD screening. First, screening for
PAD may lead to early detection and treatment of PAD before clinical presentation, which may
slow the progression of atherosclerosis and resultant functional decline. Second, because PAD is
considered an essential manifestation of systemic atherosclerosis, screening for PAD in
asymptomatic individuals may lead to early cardiovascular death (CVD) risk-factor modification
in individuals with undiagnosed atherosclerosis. The ABI is sensitive, symptom independent,
non-invasive, and cost-effective and has proven efficacy for community screening of high-risk
patients. In addition to its ability to detect PAD, an abnormal ABI may help improve the
calibration or discrimination of traditional risk-factor models to predict cardiovascular death
(CVD). It may appropriately reclassify risk in some individuals, leading to more aggressive
medical management (Haigh, 2016).
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Plans to Increase Screening
Efforts to increase screening began with updating the patient intake form. The patient's
smoking status and age were added to the already established ABI form the cardiology clinic
uses (Appendix B). The intake form was used to identify which patients met the inclusion criteria
for the project. If the patient was a smoker over 50, the medical assistant proceeded with the
ABI. Gerhard and Gornik (2017) described resting ABI as the most used screening and
diagnostic test for PAD. The ABI is the ratio of systolic blood pressure at the ankle to the
systolic blood pressure at the brachial artery. Standardized reporting improves communication
among healthcare providers. Calculated ABI values should be recorded to two decimal places.
The normal ABI is 1.0 to 1.4. Patients with ABI ≤0.90 are diagnosed with PAD. Those with ABI
0.91 to 0.99 may possibly have PAD (Appendix C). Values >1.40 indicate the arteries are not
able to be compressed, which is more common among individuals with diabetes mellitus and
advanced chronic kidney disease (Gerhard & Gornik, 2017)
Nurse's Delivery of PAD Counseling
Educating patients about PAD and its treatments should begin with explaining the
disease, risk factors, complications, and long-term effects. Patient-centered communication in
which the clinician aims to understand the individual patient's symptoms and healthcare goals
can help patients feel at ease with their care management plan. AHA (2021) acknowledges that
knowledgeable patients are more likely to discuss PAD symptoms and treatment
recommendations with healthcare professionals. Thoroughly answering questions, and asking
patients about their concerns, can also help improve adherence to medical treatments and
lifestyle changes (AHA, 2021).
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Needs Assessment
The cardiology clinic is privately owned and has no affiliation with any hospital. The
clinic prides itself on providing convenient, comprehensive cardiology care. Approximately 200
patients are seen in the clinic each month. The clinic offers comprehensive care and all
cardiovascular services, including on-site testing.
Gap Analysis
The cardiology clinic provides screening for PAD and accepts referrals to evaluate for
PAD. However, not all high-risk patients are routinely screened. The clinic currently screens
patients referred for evaluation with clear evidence of PAD or symptomatic. The patient will
either undergo an ABI screening or perform an arterial duplex. The primary population is
geriatric cardiac patients with arrhythmias, coronary artery disease, or heart failure
complications. Although the primary focus is cardiac, many patients are also seen for vascular
disease.
Mayer and Bishop (2017) revealed high-risk patients infrequently receive limb-sparing
treatments. The disease often progresses to the point of irreversible damage. Disease progression
occurs due to a lack of awareness of both patients and health care providers, limited availability
of diagnostic tests, and delayed referral for endovascular evaluation. A review of over 20,000
Medicare patients who underwent a significant amputation for critical limb ischemia showed that
71% had no revascularization attempts, and 46% had no diagnostic angiogram before a major
amputation. Another study demonstrated that primary amputation was the first procedure for
treating critical limb ischemia in 67% of Medicare patients (Mayer & Bishop, 2017).
Gerard and Gornik (2017) found that measuring the resting ABI is reasonable in patients
at increased risk of PAD but without history or physical examination findings suggestive of

13
PAD. The ABI test is non-invasive, simple to perform, has minimal risks, and is suitable for
asymptomatic individuals. Abnormal resting ABI readings are prevalent among asymptomatic
patients with risk factors for PAD. Also, asymptomatic patients with an abnormal ABI have
poorer cardiovascular morbidity and mortality outcomes than patients with normal ABI (Gerard
& Gornik, 2017).
Closing the gap and meeting the need will be achieved by identifying patients at risk for
asymptomatic PAD who may benefit from ABI screening. The modified patient intake form
determined which patients met the inclusion criteria. Mayer and Bishop (2017) discovered
millions of PAD patients are undertreated, despite proven cardiovascular risks and established
guidelines for treatment. Often patients with PAD are asymptomatic, so diagnosis frequently
occurs after permanent damage has occurred, resulting in a high rate of morbidity, amputation,
and loss of life. Early diagnosis with ongoing treatment can reduce debilitating morbidity and
improve patient outcomes (Mayer & Bishop, 2017).
SOAR Analysis
A SOAR analysis is a strategic planning framework that focuses on strengths and seeks to
understand the whole system. Using a SOAR analysis, an organization focuses on what they are
doing well, what can be improved, and what is most important to stakeholders. Using SOAR,
strategic plans can be more dynamic, creative, and optimistic (University of Missouri Library,
n.d.). SOAR is an acronym for strengths, opportunities, aspirations, and results. The SOAR
analysis conducted for the project facility revealed that the clinic's strength was screening
patients for PAD referred to the clinic. However, there was an opportunity for growth in
identifying PAD in all high-risk patients that came through the clinic. The staff aspires for
consistent, quality patient care. Through conversations, it was determined the frequency of PAD
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screening could be improved. The office staff revealed they could successfully identify PAD in
more patients by identifying high-risk patients and screening with the ABI.
Problem Statement
Gerhard and Gornik (2017) expressed that PAD is underdiagnosed, undertreated, and
underappreciated. More than one million people in the United States (U.S.) have lost a limb due
to vascular disease, including diabetes, PAD, and critical limb ischemia; approximately half of
the individuals with limb loss due to vascular disease die within five years of the amputation. Up
to 85% of these amputations could have been delayed or prevented through patient education,
lifestyle modification, early diagnosis, and endovascular intervention (Gerhard & Gornik, 2017).
Smoking is the greatest single danger to the health of the arteries. Smoking puts individuals at
higher risk for PAD. Identification of PAD, through ABI screening, improves the health of highrisk populations.
The PICOT question answered through this project was: Among smokers over 50 (P)
seen in a cardiac clinic, does the implementation of an evidence-based peripheral artery disease
screening protocol (I), versus no protocol (C), increase screening (O) of PAD over 60 days (T)?
Aims and Objectives
This project aimed to increase screening for PAD in high-risk patients. The overarching
objectives of this project were to: The objectives of this project were to (a) increase PAD
screening in adult smokers in a cardiology clinic; (b) improve utilization of the ABI to identify
PAD; (c) integrate utilization of an evidence-based PAD screening protocol; (d) demonstrate
nurse awareness and adherence regarding the delivery and effectiveness of the screening
protocol; and (e) enhance nursing documentation of peripheral artery disease counseling.
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Review of Literature
A literature review was performed with the following primary considerations: (a) best
practice in screening for PAD in high-risk patients and (b) prevalence of PAD in smokers. The
databases utilized were CINAHL and PubMed. The following key terms were used in CINAHL:
peripheral artery disease, smokers, and screening, which yielded 924 results. Results were
narrowed using peer-reviewed academic journal limits from 2016 until now, reducing potential
sources to 369. The term screening was added to the search, which narrowed the search to 13
references. Additional articles were eliminated due to content irrelevance if smoking was not a
risk factor for the patient and were not available in full text or English.
The following Mesh key terms were applied in PubMed: peripheral artery disease,
ankle-brachial index, screening, and smokers with 319 hits. The same inclusion and exclusion
criteria were applied to these articles. References of the selected papers were also searched and
evaluated for application to the study question. Results were narrowed using limits of five years
and additional modifiers to the Mesh terms: peripheral artery disease/methods, smoker/screening,
statistics, and numerical data to 46 hits. Many key findings from the literature review included
systematic reviews or guidelines suggestions. Some of the significant critical results used to
shape the methodology of this project are identified below.
Allison et al. (2020) conducted a multiracial/ethnic cohort study free of known
cardiovascular disease (CVD). This study sought to assess the disease burden of lower extremity
PAD on total mortality, incident CVD events, and CVD mortality using the non-invasive ABI in
a primary prevention population. There were six thousand eight hundred and fourteen nonHispanic White, non-Hispanic Black, Hispanic, or Chinese men and women 45–84 years of age
and free of clinically apparent CVD were recruited from six communities in the United States
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and participated in the baseline examination. To score the burden of PAD, individuals were
classified as having 0-, 1-, 2-, 3-, or 4-vessel PAD based on the number of ankle arteries with an
ABI of ≤0.9. Furthermore, individuals were classified as having unilateral PAD, bilateral PAD,
or none based on the number of legs with an ABI of ≤0.9. Of the 6,814 individuals, the authors
excluded 138, leaving a final analytical sample size of 6,527. Descriptive characteristics across
the number of vessels with PAD were computed by analysis of variance for continuous variables
and χ2 for categorical variables. Over a mean follow-up time of 13years, there were 1,202
(18.4%) deaths, of which 282 (4.3%) were CVD-related. With a mean follow-up time of 12.1
years, there were 656 (10.1%) incidents of CVD events. Of the participants, 5,711 (87.5%) had
0-vessel, 460 (7.0%) had 1-vessel, 218 (3.3%) had 2-vessel, 69 (1.1%) had 3-vessel, and 69
(1.1%) had 4-vessel PAD. Of those with 2-vessel disease, 114 (52.2%) had a traditional ABI of
>0.9 in both legs. When examining laterality, 6,285 (96.3%) had no legs with PAD, 173 (2.7%)
had unilateral PAD, and 69 (1.1%) had bilateral PAD. The authors found that multivessel PAD
had a dose-dependent association with increased risk for mortality, incident CVD events, and
CVD mortality in a diverse primary prevention population. This dose-dependent association
persisted after adjustment for potential confounders. Furthermore, the dose-dependent
association persisted even when conventional ABI values were included in the model (for
mortality) and when the analysis was restricted to asymptomatic individuals. These data
supported using all four ABI values instead of a single representative value in clinical practice
and research. Additionally, the results highlighted the prognostic importance of the magnitude of
lower extremity atherosclerosis on mortality, incident CVD, and CVD mortality (Allison et al.,
2020).
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In comparison, Kieback et al. (2019) observed the most important criterion for the
definition of PAD is an ABI reading below 0.90. Low ABI is associated with increased mortality
and morbidity. Thereby, ABI is not only a diagnostic indicator but also an important prognostic
marker. ABI measurements are rarely performed in the clinic unless the patient has mentioned
claudication symptoms. Vascular specialists usually only perform these measurements for PAD
diagnosis and follow-up after interventional or surgical PAD treatment. The meta-analysis within
the study used data from seven German population-based cohorts performed by the German
Epidemiological consortium of Peripheral Arterial Disease (GEPArD) to investigate whether one
question about claudication is more efficient for PAD screening than established questionnaires.
Claudication was defined based on the answer to one question asking for pain in the leg during
normal walking. This simple question was compared with established questionnaires, including
the Edinburgh questionnaire. The associations of claudication with continuous ABI values and
decreased ABI were analyzed by linear and logistic regression analysis. The results of the studies
were pooled in a random effect meta-analysis, which included data from 27,945 individuals
(14,052 women, age range 20–84 years). Meta-analysis revealed a significant negative
association between claudication and ABI, which was stronger in men (β = -0.07; 95% CI -0.10,
-0.04) than in women (β = -0.02; 95% CI -0.02, -0.01). Likewise, claudication symptoms were
related to increased odds of decreased ABI in both men (Odds ratio = 5.40; 95% CI 4.20, 6.96)
and women (Odds ratio = 1.99; 95% CI 1.58, 2.51). The data demonstrated that even one simple
question about claudication could help identify individuals with PAD. However, these results do
not negate the advantages of a PAD screening by ABI measurement. An ABI measurement
allows for identifying individuals with asymptomatic PAD, especially in older women.
Depending on laboratory values, ABI measurements may be less time-consuming and cheaper
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than PAD prediction models. With the availability of simple and user-friendly automated
systems for evaluating ABI, PAD screening by ABI measurements has become easier. If ABI
screenings are not established in healthcare systems, asking one quick, simple question for
claudication is preferable to no PAD screening (Kieback et al., 2019).
Jones and Patel (2018) discussed findings from the Patient‐Centered Outcomes Related to
Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT)
clinic trial. The researchers aimed to examine smoking rates and cessation interventions offered
to patients with PAD by consulting a vascular specialty clinic and assessing changes in smoking
behavior over the year following the initial visit. One thousand two hundred and seventy-two
patients with PAD and new or worsening claudication were enrolled at 16 vascular specialty
clinics. Interviews collected smoking status and cessation interventions at baseline, three, six,
and 12 months. Among smokers, transition state models analyzed smoking transitions at each
time point and identified factors associated with quitting and relapse. On presentation, 474
(37.3%) patients were active, 660 (51.9%) former, and 138 (10.8%) never smokers. Only 16%
were referred to cessation counseling among active smokers, and 11% were prescribed
pharmacologic treatment. At three months, the probability of quitting smoking was 21%; among
those continuing to smoke at three months, quitting during the next nine months varied between
11% and 12% (p<0.001). The probability of relapse among initial quitters was 36%. At
12 months, 72% of all smokers continued to smoke. More than one-third of patients with
claudication consulting a PAD provider were active smokers, and few received evidence-based
cessation interventions. Patients appeared to be most likely to quit early in their treatment course,
but many quickly relapsed, and 72% of all patients smoking at baseline were still smoking at
12 months. Better strategies were needed to provide continuous cessation support. The study
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provided current real-world data on smoking behavior and cessation practices in patients with
PAD (Jones & Patel, 2018).
In contrast, Szilagyi and Toth-Vajna (2019) indicated smoking was a significant risk
factor. Smoking increased the risk of occurrence two to six times. These risk factors further
improved with the amount and years of smoking. Smoking has a closer connection with lower
extremity PAD than with coronary diseases. The percentage of active smokers was highest in the
clear PAD-positive group, one and a half times the Hungarian average. The rate of former
smokers was also the highest, as opposed to the clear PAD-negative group, which was at half the
Hungarian average. Nearly a quarter of the population fell into the non-compressible artery and
ABI-negative symptomatic groups, defined as the 'murky zone'. When screening for PAD, these
patients deserve special attention due to the insufficient selectivity and sensitivity of
measurements. Further assessment may be considered if there is high clinical suspicion of PAD
despite typical ABI values. The general practitioner's (GP) role is vital in preventing and early
recognition of PAD. The researcher's complex approach enabled the practitioner to identify atrisk patients who belong to the 'murky zone.' These patients would remain invisible to doctors
using instrumental measurements only, requiring further examination from a differential
diagnostic perspective. In the long run, launching a complex screening program at the GP level
makes PAD patients easier to diagnose, leading to an earlier start of treatment and significantly
improving the patients' quality of life and life expectancy (Szilagyi & Toth-Vajna, 2019).
Anand et al. (2018) discovered patients with lower extremity PAD are at increased risk of
major adverse limb events (MALE). Cardiovascular Outcomes for People
Using Anticoagulation Strategies (COMPASS) was a multi-center, double-blind, randomized,
placebo-controlled trial. The authors analyzed outcomes in 6,391 patients with lower extremity
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PAD enrolled in COMPASS. A total of 128 patients experienced an incident of MALE. After
MALE, the 1-year cumulative risk of a subsequent hospitalization was 61.5%, 20.5% for
vascular amputations, and 8.3% for death. The authors found the prevention of MALE is of
paramount importance among individuals with lower extremity PAD. The prognosis after
experiencing MALE is dire, with a three-fold increase in death and a 200-fold increase in the risk
of subsequent vascular amputation, making prevention of this condition of utmost importance
(Anand et al., 2018).
Likewise, Gundrum et al. (2018) conducted an extensive, observational study to
characterize hospitalizations and outpatient endovascular revascularizations following peripheral
artery revascularization, assessing temporal trends for outcomes and identifying factors
associated with subsequent MALE hospitalization. Data for this study were from the Premier
Healthcare Database, which contained de-identified data from >687 million patient encounters or
approximately one in every five discharges in the United States. Patients ≥18 years of age with at
least one diagnosis code for PAD and one procedure code for peripheral revascularization were
discharged between January 1, 2009, and September 30, 2014, for inclusion in this study.
Multivariable logistic regression was used to identify factors associated with hospitalization for
MALE within one year after discharge from the index encounter. In this study of 381,415
patients undergoing peripheral artery revascularization, subsequent hospitalizations and
outpatient endovascular revascularization procedures were common. Within one year after the
index revascularization, many patients were hospitalized for limb-related and cardiovascular
causes, with one in 10 admitted for MALE. Although subsequent hospitalizations trended down
during the study period, the residual risk for post-procedure limb-related and cardiovascular
events remained high. The authors identified multiple demographic, patient, and procedural
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factors associated with MALE's one-year hospitalization risk. Based on these findings, efforts to
reduce the burden of comorbidities, improve surgical revascularization techniques and
implement a multidisciplinary approach to the care of PAD patients represented actionable
strategies to reduce hospitalization for MALE (Gundrum et al., 2018).
Lee and Lin (2016) conducted a retrospective cohort study. The study was conducted at
the Division of Endocrinology and Metabolism in Taichung Veterans General Hospital. The
researchers reviewed the medical records of adults who had undergone ABI assessment because
they were suspected of having a high risk of PAD based on their clinical manifestations,
including intermittent claudication, pulseless, pallor, paralysis, or paresthesia in the lower
extremities. A total of 314 participants were included in the analyses. The χ2 test examined
differences in categorical variables across study groups. Participants with ABI ≤0.9 showed the
highest mortality rate (45%) and higher risk of all-cause mortality after adjustment for ABI,
pulse wave velocity, age, sex, blood pressure, serum cholesterol, and history of cardiovascular
disease and diabetes. The researchers demonstrated a high percentage of mean arterial pressure
based on pulse volume recording in participants with ABI<0.9 could predict all-cause mortality
during 20.3 months of follow-up (Lee and Lin, 2016).
Similarly, in a cross-sectional analysis, Mostaza and Rio (2017) acknowledged an ABI
<0.90 indicated the presence of a flow-limiting arterial disease affecting the limb. The authors
also found the accuracy of the ABI for detecting >50% stenosis in the leg arteries is high, with a
75% sensitivity and 86% specificity. One thousand five hundred and sixty-eight subjects (43%
males) were randomly selected from the population. A fasting blood sample was obtained to
determine glucose, lipids, and HbA1C levels. An oral glucose tolerance test was performed on
non-diabetic subjects. PAD was evaluated by ankle-brachial index or having a prior diagnosis.
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PAD prevalence was 3.81% (95% CI, 2.97–4.87). In men, PAD prevalence was significantly
higher than in women [5.17% (95% CI, 3.74–7.11) vs. 2.78% (95% CI, 1.89–4.07); p = 0.014].
There were statistically significant differences between ABI categories concerning smoking
status. The analysis revealed that ABI was a consistent independent risk factor for cardiovascular
events and mortality. Furthermore, the ABI is recommended to detect subclinical PAD and offer
early therapeutic interventions to lower the risk of cardiovascular events and mortality. The
positive association between smoking status and PAD is well established and habitually found in
most research studies, and this study is consistent with these findings (Mostaza & Rio, 2017).
Szilagyi and Toth-Vajna, (2019) conducted a qualitative study that revealed lower
extremity PAD is often diagnosed late in general practice. Current recommendations suggest the
use of non-invasive ABI measurement for screening. The ABI measurement of sensitivity and
specificity for lower extremity PAD can be estimated between 79% and 96%. ABI may indicate
abnormalities even before the patient develops complaints of claudication. Based on ABI
measurements, the study categorized nearly a quarter of all examined patients into the clear
PAD-positive group. Eight hundred and sixteen patients were screened. The researchers used the
Edinburgh Questionnaire and recorded medical histories, major risk factors, current complaints,
and medication. Physical examinations were performed, including ABI testing. Thirty-three
percent complained about lower extremity claudication, 23% had abnormal ABI values, 13% of
the patients within the normal ABI range had complaints of dysbasia, and 12% were in the noncompressible artery group. The ABI-negative symptomatic group's risk factor profile was similar
to the clear PAD-positive and non-compressible artery groups. These findings match the data of
similar analyses. It is important to note a quarter of these patients were asymptomatic, as the lack
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of complaints further hinders the recognition of PAD by the general practitioner (Szilagyi &
Toth-Vajna, 2019).
Chen et al. (2019) summarized the Atherosclerosis Risk in Communities (ARIC) study
that enrolled 15,792 participants aged 45 to 64 from four U.S. communities. In this communitybased cohort with nearly three decades of follow-up, all smoking measures (pack-years, duration,
intensity) demonstrated considerably stronger associations with PAD than coronary heart disease
(CHD) or stroke. Baseline characteristics of the study population were compared according to
smoking status (current, former, never) at baseline. Cox regression models were used to quantify
the associations between smoking measures (pack-years of smoking, duration, intensity
[packs/day], and cessation) and the incidence of PAD. Smoking cessation was associated with
the most significant risk reduction for PAD among these atherosclerotic diseases. Compared with
current smokers, those with smoking cessation for five to <10 years showed a hazard ratio of
∼0.4 for PAD (Chen et al., 2019).

According to Chen et al. (2019), a significantly elevated risk was observed for up to 30

years for PAD with never smokers as a reference. The results further highlighted the importance
of smoking prevention and early smoking cessation. The authors indicated the need for public
statements to consider PAD when acknowledging the impact of smoking on overall
cardiovascular health. All smoking measures tested in the study were strongly associated with a
long-term risk of three major atherosclerotic diseases, but the association was robust for PAD.
The elevated risk of PAD was prolonged up to 30 years after smoking cessation. The study
provided evidence for an anti-smoking campaign to continue to advocate smoking prevention
and cessation. Although public statements about smoking have focused on coronary artery
disease and stroke, these results indicated the need to take account of PAD and comprehensively
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acknowledge the effect of smoking on overall cardiovascular health. The results of this cohort
study have important public health implications. It is essential to recognize that the risk of
atherosclerotic diseases started to decline after smoking cessation in a short timeframe of <5
years, which would encourage persons attempting or considering quitting smoking (Chen et al.,
2019).
Duval et al. (2015) equally correlated tobacco use to increased PAD-related
hospitalizations, coronary heart disease, PAD procedures, and significantly greater costs. A
retrospective, cross-sectional study design was used. The researcher restricted the study
population to individuals with 12 months of continuous plan enrollment to assure that clinical
event and cost data collection were maximally complete. The primary study population focused
on all continuous medical plan enrollees (the total PAD cohort). A PAD cohort of 22,203 was
identified, comprising 1,995 (9.0%) tobacco users. A subgroup of 9,027 with pharmacy benefits
included 1,158 (12.8%) tobacco users. The total cohort experienced 22,220 hospital admissions.
The pharmacy benefits subgroup experienced 8,152 admissions. Within one year, nearly one-half
of the PAD tobacco users were hospitalized, 35% higher than nonusers in the total cohort (p <
0.001) and 30% higher in the subgroup (p < 0.001). In both cohorts, users were more frequently
admitted for peripheral or visceral atherosclerosis (p < 0.001). Observed costs in the total cohort
were $64,041 for tobacco users versus $45,918 for nonusers. Tobacco users' costs were also
consistently higher for professional and facility-based care, persisting after adjustment for age,
sex, comorbidities, and insurance type. Tobacco use in patients with PAD is associated with a
considerable increase in hospitalized clinical events. When individuals with PAD smoke, a much
higher fraction of hospitalized events are due to adverse cardiac and PAD ischemic events. The
tobacco-related detrimental health impact was associated with a substantial 30% increase in
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annual health expenditures. This smoking-attributable health and economic burden strongly
suggested that tobacco cessation programs would be especially cost-effective for this population
(Duvall et. at, 2015)
In summary, lower extremity PAD is a global public health issue that has been
systematically understudied and underappreciated. Healthcare professionals, researchers, expert
organizations, healthcare organizations, government agencies, industry, and the community
should collaborate to increase the awareness and understanding of PAD and improve the quality
of PAD diagnosis, management, and prognosis. Key findings in the literature review supported
implementing a PAD screening protocol utilizing the ABI. Research indicated early
identification of PAD through screening significantly improved patient outcomes.
Theoretical Model
The theory utilized to guide this project is Jean Watson's Theory of Human Caring.
Nursing is defined by caring. Caring is a mutually beneficial experience for the patient, the
nurse, and health team members. For Watson, the transpersonal caring relationship characterizes
a special human care relationship. It describes how the nurse goes beyond an objective
assessment, showing concerns toward the person's subjective and deeper meaning regarding their
health care (Ryan, 2016).
Ozon (2015) stated Jean Watson's theory of caring provides nurses with a moral compass
from which to work. It helps nurses bring a humanistic and philosophical piece to their patients'
care. This theory helps frame this project by listening to patients, seeing the person behind the
disease, and paying attention to their actions, allowing them to take care of themselves.
Identifying high-risk patients and performing the ABI exudes compassion and caring (Ozon,
2015).
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Watson (2012) embraces the mind/body/spirit approach to healing that guides nurses in a
holistic approach to their jobs. The caring theories proposed by Watson encourage nurses to
integrate their compassion and spirituality into their practices as an adjunct to the science of
medicine. Watson's theory is a reminder that the primary purpose of health care professionals is
not to assess vital signs or fill out forms but to help people heal and provide comfort for these
people. (Watson, 2012).
Methodology
This process change DNP project improved adherence to an evidence-based PAD
screening protocol. The primary intervention of this project increased the utilization of an
evidence-based PAD screening protocol for smokers in a cardiology clinic. The literature has
been referenced for best practices and guidelines to achieve the aims and objectives.
Setting
The clinical setting where this project took place was a privately owned suburban
cardiology clinic. The patients in the cardiology clinic have various medical problems, but the
focus of care was cardiovascular. The daily census averaged two to five new patients a day.
Population
The population of interest was adult smokers aged 50 and older who were new patients to
the clinic. Table A below outlines the inclusion and exclusion criteria that guided nurses when
identifying patients for this intervention.
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Table A: inclusion and exclusion criteria
Inclusion Criteria

Exclusion Criteria

Age 50 and older

Less than 50 years old

Smoker

Non-Smoker

New patient

Established patient

Consent
Consent and agreement to participate were obtained from all study participants before the
project intervention (Appendix D). It was emphasized that this was a DNP student project to
standardize routine PAD screenings on high-risk patients. The principal investigator (PI) running
this project had no influence over administrative responsibilities in the cardiology clinic
concerning scheduling, staffing, evaluation(s), and promotion(s). It was conveyed to staff nurses
that the cardiology clinic had no influence or participation in this project. The PI maintained
privacy and confidentially of all identifiable collected data.
Design
Knowledge-to-Action (KTA) was utilized as the implementation framework for this
project. KTA consists of two components, knowledge creation and an action cycle. Daya and
White (2020) explained knowledge creation aims to create 'knowledge tools', such as practice
guidelines or training courses. Knowledge creation is the descriptive process by which
knowledge about an intervention passes through several stages: accumulative evidence,
aggregation of evidence, and practical synthesis of evidence. The action cycle describes a
dynamic knowledge application process designed to change current ways of doing things so that
innovative, evidence-based interventions are used in practice (Daya & White, 2020).

28
The process change project used a sampling of patients in a cardiology clinic. Before
implementation, the investigator received project approval from the Jacksonville State University
Institutional Review Board (Appendix F). The goal of this process change was an early diagnosis
and appropriate referrals to improve patient outcomes. The process change project began by
performing a retrospective chart review. Charts were reviewed for 60 days, utilizing the same
inclusion criteria used in implementation, to gather pre-implementation data regarding the
number of patients screened for PAD.
Chart Review
A retrospective chart review was performed to analyze how many new, high-risk patients
were seen over 60 days and were screened for PAD. Instead of screening every high-risk patient,
the office was screening patients referred for evaluation, having clear PAD evidence, or being
symptomatic. During the 60-day chart review, the identified gap in practice was a lack of routine
screening for PAD in high-risk patients. High-risk patients were identified as smokers aged 50
and older. Approximately 30 new patients were seen in the clinic each month, but only 5% of
those patients were screened for PAD.
Risks, Benefits, and Compensation
There was no risk for any of the patients participating in this project. Benefits include
early diagnosis, which leads to early intervention and improves patient outcomes by preventing
complications associated with PAD. There was no compensation for any participant in this
project.
Timeline
The timeline table delineates the required proposal and project components and
incorporated course, college, and university deadlines. The timeline established expectations by
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providing an overview of the DNP project process requirements from the project proposal
through dissemination (Appendix E).
Budget and Resources
It was essential to consider the budget and available resources, as with any project. Most
times, the cost associated with a DNP project is nominal. In general, budgets consider both
expenses and revenue related to the project. These expenses include direct and indirect costs. The
clinic absorbed the minimal cost of the project. The final expenditure was $5.00 for paper and
ink.
Evaluation Plan
Statistical Considerations
The PAD screening and detection rates between the pre-intervention and postintervention groups were compared using Fisher's Exact Test. The rates were calculated using
frequency and percentage statistics. All analyses were performed using SPSS Version 28
(Armonk, NY: IBM Corp.), and statistical significance was assumed at an alpha value of 0.05.
Data Maintenance and Security
After the project was completed, the IRB was closed, and the final manuscript was
completed. All data was destroyed following the clinic's guidelines. Hard copies of data,
including patient medical record numbers and nurse employee numbers, did not leave the clinic
and were destroyed via clinic policy.
Results
There was a statistically significant increase in the rate of screenings from preintervention (3.4%) to post-intervention (47.6%), X2(1) = 11.39, p = 0.0007. There was no
difference between the pre-intervention group (3.4%) and the post-intervention group (19.0%) on

30
the detection of PAD, X2(1) = 1.79, p = 0.18. The rates of the outcomes are presented graphically
below in Figure 1.
Figure 1: Statistical analysis of pre-and post-intervention
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30%
Pre-itervention

25%

Post-intervention

20%
15%
10%
5%
0%

Screening

PAD

Discussion
This project sought to address the lack of PAD screening in high-risk patients in a
cardiology clinic. The main aims were to increase screenings of smokers aged 50 and older and
identify those patients who have PAD. With a p-value of 0.0007, the statistical analysis provided
evidence the project successfully increased the rate of PAD screenings in high-risk patients.
Quantitative data was used to measure the ability of this project to meet those aims. The DNP
process change project was influential in helping the staff screen high-risk patients. While there
was no statistical significance, with a p-value of 0.18 in pre-intervention and post-intervention
data on the rate of PAD detection, there was clinical significance. The patients identified as
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having severe PAD were referred to the appropriate interventionalist. Early identification and
treatment improved patient outcomes.
Implications for Clinical Practice
The project's aims were met by demonstrating an increase in screening for PAD among
smokers 50 years old and older. This project showed the importance of screening for PAD in
smokers and identifying those high-risk patients and offered an increase in PAD identification.
The literature review of evidence-based research indicated identifying PAD early improved
patients' outcomes. This project enhances the existing literature and continues to show the
importance of screening.
Implications for Healthcare Policy
CMS has policies regarding non-invasive vascular studies. These studies are considered
medically necessary if the ordering physician has reasonable expectations that their outcomes
will potentially impact the patient's clinical management. Services are deemed medically
necessary when significant signs/symptoms of arterial or venous disease are present. There is
room for improvement when deciding what is medically necessary. The research demonstrates
patients can have PAD without significant signs/symptoms. Therefore, routine screening should
be performed on all high-risk patients. Smoking cessation education should be discussed at all
visits, as this is a modifiable risk factor and has the potential to improve patient outcomes
significantly.
Implications for Quality/Safety
This process change DNP project improved the consistency of screening high-risk
patients for PAD, which led to PAD identification in more patients. Improving patient outcomes
should always be at the forefront of healthcare. PAD screening is a simple, cost-effective tool
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that can significantly improve the quality of a patient's everyday life. The ABI poses no harm to
the patient and is a safe, effective way to identify PAD. Smoking is one of the most correlated
risk factors, and increasing the patient's knowledge of the impact of tobacco can reduce future
complications.
Implications for Education
Multiple studies demonstrated the need for education regarding the prevalence of PAD in
high-risk patients. Smoking is the single most modifiable risk factor for the development of
PAD. This DNP process improvement project further supported this by bridging the gap between
evidence and practice. As evidenced by the findings in the statistical analysis, this project
translated the evidence into practice and further supported the need for routine PAD screening in
smokers.
Limitations
Limitations of this project included the small sample size of patients. Due to the
unexpected closure of the clinic, the post-implementation data collection time frame was limited
to 30 days. Additionally, the project was implemented in only one clinic in a suburban setting.
This project could be held in a larger metropolitan facility with more participants to increase
generalizability.
Dissemination
The findings of this research study have been disseminated through the three P's: poster,
presentation, and paper. The DNP Project was presented via poster and short presentation at the
University's Virtual Dissemination Day. Additionally, the DNP manuscript was placed in the
Jacksonville State University's Digital Commons repository. Another path of dissemination, such
as the utilization of social media, may be explored.
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Sustainability
The DNP process improvement project aligned with the clinic's philosophy and mission;
however, implementation ended abruptly, with the clinic closing permanently and giving the
staff only a 10-day notice. This project has many opportunities for sustainability, as screening for
PAD in high-risk patients can occur in any environment. The screening should not be limited to
the cardiology setting. There is an excellent opportunity for sustainability in urgent care, family
practice, and pain clinics. Gerhard and Gornik (2017) stated the AHA and American College of
Cardiology (ACC) guidelines also support screening for PAD in people aged 65 and older, age
50–64 years with risk factors for atherosclerosis (e.g., diabetes mellitus, history of smoking,
hyperlipidemia, hypertension) or family history of PAD, age <50 years with diabetes mellitus
and one additional risk factor, and individuals with known atherosclerotic disease (Gerhard &
Gornik, 2017).
Plans for Future Scholarship
Future research with a larger sample size is recommended to determine if the results are
related to screening early in the year when deductibles have not been met, and patients are less
likely to visit the doctor. The study was cut short due to the office closing permanently, so it is
also recommended to repeat the study for an extended time. While this DNP process
improvement project adds to the existing data supporting the need for PAD screening in highrisk patients, further research is needed to stress the importance of these findings. There is a lack
of awareness of PAD. This project suggests room for improvement in the primary care diagnosis
of symptomatic PAD. This could be achieved by clinicians simply asking about claudication
symptoms during routine consultations. Practical strategies to raise public awareness of this
disease are also needed. On a simplistic level, this could involve displaying PAD posters in
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general practice waiting rooms and pharmacies; more sophisticated strategies, such as social
media, could also be developed and implemented.
Conclusion
In conclusion, Bevan and White Solaru (2020) agreed PAD is a devastating disease with
high morbidity and mortality. Tobacco smoke increases endothelial cell permeability by forming
reactive oxygen species, enabling atherosclerosis to settle within vessel walls. The magnitude of
this effect is clinically evident, with the prevalence of PAD increasing two to three times in
current smokers. Smoking promotes PAD and augments complication rates. Despite the
multitude of medical treatment options available, PAD is chronically undertreated. Future
advancements in management strategies and improved application of available medical therapies
will prevent complications and improve the quality of life for patients with PAD (Bevan &
White Solaru, 2020). This DNP project illustrated the importance of routine PAD screening in
smokers. It also demonstrates the need for smoking cessation. Expanding this project to other
high-risk groups will be essential moving forward when chronic disease is rising.
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Appendix A
Screening Recommendations for PAD
Organization Name

Recommendation

American College of Cardiology and
American Heart Association

Screen adults ≥65years old, adults ≥ 50 years
old with a history of diabetes, and adults of
any age with exertional leg symptoms or nonhealing wounds (American Heart Association,
2021).
Screen patients with diabetes who are
symptomatic or are asymptomatic and > 50
years old or have at least one other risk factor
(smoking, hypertension, hyperlipidemia, or
duration of diabetes) > 10 years (American
Heart Association, 2021).
Screen symptomatic patients or are
symptomatic and > 65 years old or >50 years
old with risk factors or a family history of
PAD (American Heart Association, 2021).

American Diabetes Association

European Society of Cardiology
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Appendix B
Patient Intake Form
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Appendix C
ABI Interpretation
ABI Value

Interpretation

Recommendation

Greater than 1.4

Calcification/Vessel

Refer to a vascular specialist

hardening
1.0-1.4

Normal

None

0.9-1.0

Acceptable

None

0.8-0.9

Some arterial disease

Treat risk factors

0.5-0.8

Moderate arterial disease

Refer to a vascular specialist

Less than 0.5

Severe arterial disease

Refer to a vascular specialist

41
Appendix D
Consent and Agreement to Participate
Participant Consent Form
TITLE OF STUDY: Project Ankle-Brachial Index: Implementation of an evidence-based
peripheral artery disease protocol.
Care Setting
Principal Investigator: Rene Banks, CRNP
This consent form is part of an informed consent process for a DNP student project, and it will
provide information that will help you decide whether you wish to volunteer for this project. It
will help you understand what the study is about and what will happen during the project. If you
have questions at any time during the project, you should feel free to ask them and should expect
to be given answers that you understand entirely. You are not giving up any of your legal rights
by volunteering for this research project.
Why is this project being done?
This project aims to address the lack of consistency in screening for peripheral artery disease in a
cardiology clinic. A lack of structure and guidelines within a clinic setting leaves room for
omitting proper screening. This project plans to improve screening of peripheral artery disease
over 50 that smoke. This study also plans to improve the early identification of peripheral artery
disease in high-risk patients. The study will run for 60 days with an estimate of 40-50 patients
involved.
What will you be asked to do if you take part in this research project?
If you are identified as a smoker over the age of 50, the medical assistant will then proceed with
the ankle-brachial index test. The ankle-brachial is the most used screening and diagnostic test
for peripheral artery disease and will be performed by taking a series of blood pressure readings
in your legs and arms. The PI will then provide an educational session that will include results of
the ankle-brachial index score, smoking cessation, and any further diagnostics that may be
needed, depending on your score.
What are the risks or discomforts you might experience if you take part in this project?
No expected harm can occur from participating in this study. This project has no influence or
involvement from upper management, and participation is voluntary. Upper management will be
excused from participation and not provided any information regarding survey results or nurse
participation in this project. Participation in this project is of no cost to you.
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How will information about you be kept private or confidential?
All efforts will be made to keep your personal information in your research record confidential,
but total confidentiality cannot be guaranteed. Only a patient number will be placed on your
intake form without the addition of any other personal identifiers. Scores will remain within the
clinic, and information will not be removed from the premises until all identifiable information is
removed.
What will happen if you do not wish to participate in the project or if you later decide not
to stay in the project?
Participation in this project is voluntary. Suppose you do not want to enter the project or decide
to stop participating. You may choose not to participate, or you may change your mind at any
time. In that case, your relationship with the study staff will not change, and you may do so
without penalty and without loss of benefits to which you are otherwise entitled.
You may also withdraw your consent for the use of data already collected about you, but you
must do this in writing to Rene Banks at mbanks@jsu.edu.
Who can you call if you have any questions?
If you have any questions about taking part in this project you can call the principal investigator:
Rene Banks, CRNP
Cardiology Clinic
245-996-0415
AGREEMENT TO PARTICIPATE
1. Subject consent: I have read this entire form, or it has been read to me, and I
believe I understand what has been discussed. All of my questions about this form or
this study have been answered. I agree to take part in this research study.
Subject Name:
Subject Signature:

Date:

2. Signature of Investigator/Individual Obtaining Consent: To the best of my
ability, I have explained and discussed the study's complete contents, including all of
the information contained in this consent form. All questions of the research subject
and those of their parent or legally authorized representative have been accurately
answered.
Investigator/Person Obtaining Consent (printed name):
Signature:
________________________

Date: __________
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Appendix E
Timeline
Completion

Pre-Design

Summer 2021

Define the
clinical problem.

DNP 796

Fall 2021
DNP 797

Design

Implementation

Evaluation

Implement the
DNP project.

Data collection and
statistical analysis.

Develop the
initial PICOT.
Complete an
initial review of
the literature.
Finalized PICOT
question.
Communicated
with university
faculty about
project ideas.
Met with
preceptor and
office staff.

Began the draft
of the project
proposal.
Obtained PERC
approval.
Obtained IRB
approval.

Additional
review of the
literature.
Select theoretical
methodology.

Spring 2022
DNP 798

Summer 2022
DNP 799

Complete CITI
training

Final project manuscript
submission.
Project dissemination,
poster presentation, and
submission of ePortfolio.
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Appendix F
IRB Approval Letter

